Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 4/20 | 0.72 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.72 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.72 |
| ▸ | GAA | P10253 | 3/20 | 0.70 |
| ▸ | HPGD | P15428 | 3/20 | 0.63 |
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | NPC1 | O15118 | 2/20 | 0.61 |
| ▸ | RAB9A | P51151 | 2/20 | 0.61 |
| ▸ | HTR2B | P41595 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 5/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.56 |
| ▸ | GFER | P55789 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.53 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5823073 | 0.86 | CYP2C9 (0.77) | CYP2C9CYP2C19MAPK14NPC1HTR2B | |
| SCHEMBL5820252 | 0.86 | CYP2C9 (0.77) | CYP2C9CYP2C19MAPK14HTR2BMEN1 | |
| SCHEMBL7234983 | 0.84 | CYP2C9 (1.00) | CYP2C9CYP2C19MAPK14GAALMNA | |
| SCHEMBL5821507 | 0.82 | CYP2C9 (0.71) | CYP2C9CYP2C19MAPK14NPC1HTR2B | |
| SCHEMBL1063428 | 0.78 | MAPK14 (0.72) | CYP2C9CYP2C19MAPK14NPC1HTR2B | |
| SCHEMBL7604997 | 0.77 | CYP2C9 (0.77) | CYP2C9CYP2C19MAPK14GAAHTR2B | |
| SCHEMBL7231606 | 0.77 | CYP2C9 (0.69) | CYP2C9CYP2C19MAPK14GAAHTR2B | |
| SCHEMBL10720113 | 0.76 | CYP2C9 (0.81) | CYP2C9CYP2C19MAPK14LMNAHTR2B | |
| SCHEMBL3492151 | 0.76 | MAPK14 (0.68) | CYP2C9CYP2C19MAPK14NPC1HTR2B | |
| SCHEMBL3883491 | 0.75 | MAPK14 (0.60) | CYP2C9CYP2C19MAPK14TSHRNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 184 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250215397-A1 | TWO-DIMENSIONAL CULTURE METHOD HAVING CLEAR CHEMICAL COMPOSITION FOR CULTURING THREE-DIMENSIONAL INTESTINAL ORGANOID-DERIVED INTESTINAL STEM CELL AGGREGATE | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2025-07-03 | — | — | US | claimed |
| CN-119698462-A | Two-dimensional culture method with definite chemical composition for culturing three-dimensional intestinal organoid derived intestinal stem cell population | 韩国生命工学研究院 | 2025-03-25 | — | — | CN | claimed |
| US-12145981-B2 | Methods and compounds for the treatment or prevention of severe influenza | Poolbeg Pharma (UK) Limited (GB) | 2024-11-19 | — | — | US | claimed |
| US-12091719-B2 | Compositions and methods for detecting viruses in a sample | WASHINGTON UNIVERSITY (US) | 2024-09-17 | — | — | US | claimed |
| EP-4416268-A1 | METHODS FOR PRODUCING CARTILAGE AND BONES | Murdoch Children's Research Institute (AU) | 2024-08-21 | — | — | EP | claimed |
| CN-118355110-A | Method for producing cartilage and bone | 默多克儿童研究所 | 2024-07-16 | — | — | CN | claimed |
| WO-2024112170-A1 | METHOD FOR NON-XENOGENEIC CULTURING OF INTESTINAL STEM CELLS ON SURFACE COATED WITH THIN FILM | 한국생명공학연구원 | 2024-05-30 | — | — | WO | claimed |
| CN-116942832-A | Novel anti-infective strategy for combined infection of influenza virus and staphylococcus aureus | 归属疗法有限公司 | 2023-10-27 | — | — | CN | claimed |
| US-20230285556-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | OMEROS CORPORATION | 2023-09-14 | — | — | US | claimed |
| WO-2023153737-A1 | TWO-DIMENSIONAL CULTURE METHOD HAVING CLEAR CHEMICAL COMPOSITION FOR CULTURING THREE-DIMENSIONAL INTESTINAL ORGANOID-DERIVED INTESTINAL STEM CELL AGGREGATE | 한국생명공학연구원 | 2023-08-17 | — | — | WO | claimed |
| WO-2023060322-A1 | METHODS FOR PRODUCING CARTILAGE AND BONES | MURDOCH CHILDREN'S RESEARCH INSTITUTE (AU) | 2023-04-20 | — | — | WO | claimed |
| WO-2023039578-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | OMEROS CORPORATION (US) | 2023-03-16 | — | — | WO | claimed |
| US-20220275062-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OR PREVENTION OF SEVERE INFLUENZA | ORPH PHARMA IP COMPANY LIMITED (GB) | 2022-09-01 | — | — | US | claimed |
| US-11339207-B2 | Methods and compounds for the treatment or prevention of severe influenza | ORPH PHARMA IP COMPANY LIMITED (GB) | 2022-05-24 | — | — | US | claimed |
| US-20220096590-A1 | NOVEL-ANTI-INFECTIVE STRATEGY AGAINST INFLUENZA VIRUS AND S. AUREUS COINFECTIONS | ATRIVA THERAPEUTICS GMBH (DE) | 2022-03-31 | — | — | US | claimed |
| US-20160137982-A1 | P38 MAPK INHIBITOR-CONTAINING MEDIUM AND METHOD FOR OSTEOGENIC DIFFERENTIATION | TAMPEREEN YLIOPISTO (FI) | 2016-05-19 | — | — | US | claimed |
| EP-2834349-B1 | P38 MAPK INHIBITOR-CONTAINING MEDIUM AND METHOD FOR OSTEOGENIC DIFFERENTIATION | TAMPEREEN YLIOPISTO (FI) | 2016-04-20 | — | — | EP | claimed |
| EP-2834349-A1 | P38 MAPK INHIBITOR-CONTAINING MEDIUM AND METHOD FOR OSTEOGENIC DIFFERENTIATION | Tampereen Yliopisto (FI) | 2015-02-11 | — | — | EP | claimed |
| WO-2014202837-A1 | P38 MAPK INHIBITOR-CONTAINING MEDIUM AND METHOD FOR OSTEOGENIC DIFFERENTIATION | TAMPEREEN YLIOPISTO (FI) | 2014-12-24 | — | — | WO | claimed |
| WO-2014122298-A1 | INTERLEUKIN-4 INHIBITORS FOR THE TREAMTENT OF NEUTROPENIA | Universität Zürich (CH) | 2014-08-14 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12145981-B2 | Methods and compounds for the treatment or prevention of severe influenza | CXCL10, MAPK10, CCL11 | CYP2C9 4152/4885CYP2C19 3660/4885MAPK14 14/4885 |
| US-20230285556-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | TP53, CD4, MCL1 | CYP2C9 4493/4885CYP2C19 4433/4885MAPK14 4032/4885 |
| US-20220096590-A1 | NOVEL-ANTI-INFECTIVE STRATEGY AGAINST INFLUENZA VIRUS AND S. AUREUS COINFECTIONS | MAPK1, MAP2K1, MAP2K6 | CYP2C9 3464/4885CYP2C19 2991/4885MAPK14 14/4885 |
| US-20220275062-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OR PREVENTION OF SEVERE INFLUENZA | CXCL10, MAPK10, CCL11 | CYP2C9 4152/4885CYP2C19 3660/4885MAPK14 14/4885 |
| US-11339207-B2 | Methods and compounds for the treatment or prevention of severe influenza | CXCL10, MAPK10, MAPK1 | CYP2C9 4041/4885CYP2C19 3554/4885MAPK14 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.